ImmunoCellular Therapeutics VP Buys $10,010 in Stock (IMUC)
ImmunoCellular Therapeutics (NASDAQ:IMUC) VP Anthony Gringeri purchased 11,000 shares of the stock in a transaction dated Thursday, August 21st. The stock was purchased at an average price of $0.91 per share, with a total value of $10,010.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
ImmunoCellular Therapeutics (NASDAQ:IMUC) traded up 1.94% on Tuesday, hitting $0.9297. 60,401 shares of the company’s stock traded hands. ImmunoCellular Therapeutics has a 1-year low of $0.65 and a 1-year high of $4.00. The stock’s 50-day moving average is $0.96 and its 200-day moving average is $1.16. The company’s market cap is $56.4 million.
ImmunoCellular Therapeutics (NASDAQ:IMUC) last released its earnings data on Monday, August 11th. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.06) by $0.02. On average, analysts predict that ImmunoCellular Therapeutics will post $-0.22 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. ImmunoCellular Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $3.31.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.